Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models

Fig. 5

Functional proteomics of MCF-7 xenograft demonstrating in vivo effects of ALRN-6924 combined with paclitaxel on proliferative markers and cell cycle regulators. a Heat map demonstrating 28 DEPs (ALRN-6924 vs vehicle control) which was generated by unsupervised hierarchical cluster analysis of RPPA obtained from pharmacodynamics studies. Scatter plots based on RPPA data of MCF-7 pharmacodynamics study depicting in vivo p53, p21, c-Myc, and p-Rb activity. Mean ± SD is shown (n = 4–5). b Heat map showing 29 DEPs (ALRN+paclitaxel vs paclitaxel). Scatter plots demonstrating in vivo mTOR pathway activity after vehicle, ALRN-6924, paclitaxel, or combination of both treatments. Mean ± SD (n = 4–5) is shown

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us